Condition
Hemoglobin S Disease
Total Trials
4
Recruiting
1
Active
1
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (3)
Trial Status
Completed2
Recruiting1
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04201210Phase 2Recruiting
A Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With SCD
NCT02571088Not ApplicableCompleted
Evaluation of a Training Program for Homozygous Sickle Cell Disease Patients
NCT01601340Phase 2Terminated
Effects of HQK-1001 in Patients With Sickle Cell Disease
NCT01322269Phase 2Completed
A Study of HQK-1001 in Patients With Sickle Cell Disease
Showing all 4 trials